Close
Novotech
Jabsco PureFlo 21 Single Use

Research Insight

Navigating Russia’s Compliance Regulations; Arguably the Most Complex in the World

Russia’s increasing reliance on pharmaceutical-driven healthcare is resulting in a growing consumer demand for drugs of all types. Over the past few decades, the country’s domestic pharmaceutical market has shifted, maturing into a model more closely aligned with those of...

Lonza and AllCells Join Forces for Global Commercialization of Hematopoietic Primary Cells

Lonza and AllCells have entered into a private label partnership for the manufacture and global commercialization of an extensive range of hematopoietic primary cells. This partnership expands Lonza’s broad offering of hematopoietic cell lines and enables...

New Study Findings Show Mixture of DuPont Probiotic Strains and Lactoferrin Reduces Common Cause of Vaginal Discomfort

New findings from a Giellepi Health Science Division clinical research trial demonstrates that a mixture of probiotic strains and lactoferrin could aid in reducing the most common cause of vaginal discomfort in women. Bacterial vaginosis (BV)...

WuXi AppTec Expands Site in California for Pharmaceutical R&D Services

WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces the expansion of its facilities in San Diego, California. WuXi AppTec’s newly expanded facility will establish a...

Eisai and UCLommence preparations for phase i clinical studies in Alzheimer’s Disease for Novel Anti-Tau Antibody

Eisai Co., Ltd  and University College London   announced  that they have commenced preparations for Phase I clinical studies on E2814 The first clinical candidate from their drug discovery collaboration, in Alzheimer’s disease patients within fiscal 2018....

ADC Bio secures additional equity round investment

ADC Biotechnology , announces that it has secured additional funding of £2.5 million from existing investors and company management. The investment syndicate consists of Maven Capital Partners, Seneca Partners, the Development Bank of Wales and Downing...

Protagen AG collaborates with UCSF to study better immuno-profiling of cancer patients receiving immunotherapy

Protagen AG has announced the start of a collaboration with the University of California, San Francisco (UCSF) to utilize Protagen’s SeroTag® technology to investigate the immuno-profiling of prostate cancer patients treated with checkpoint inhibitors and therapeutic vaccines. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »